PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 12, 20250 citations

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

View Full Paper
NSNiccolò G. SantinNSNamrata SethiSBStefania Bellone

Key Points

  • Significant ADCC was observed only in TROP2-positive endometrial cancer cell lines.
  • Evaluated three endometrial cancer cell lines, with ADCC measured in the presence of PBMCs.
  • Datopotamab deruxtecan demonstrates potential as an effective treatment for TROP2-targeted endometrial cancers.
  • Results indicate the importance of TROP2 expression for the efficacy of antibody-drug conjugates.

Abstract

ADCC results of Dato-DXd, CTL-ADC, datopotamab, and rituximab (anti-CD20) in three representative endometrial cancer cell lines (A) END(K)34 TROP2-negative cell line, (B) END(K)254 TROP2 3+ cell line, and (C) END(K)265 TROP2 3+ cell line in the presence of PBMCs. Significant ADCC was detectable only against the TROP2-positive cell lines (B and C; *, P

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Santin et al. (2025) studied this question.

synapsesocial.com/papers/68d44b3031b076d99fa54926https://doi.org/10.1158/2767-9764.30102512
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  2. 2Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  3. 3Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  4. 4Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025
  5. 5Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas2025